Epigenetic clocks based on DNA methylation (DNAm) are increasingly utilized in aging research to estimate biological age. This study investigates the differences in age estimation across three generations of epigenetic clocks: the first-generation Horvath clock, the second-generation PhenoAge clock, and the third-generation DunedinPoAm clock. The research focuses on how these clocks compare in estimating deviations between chronological age and DNAm age, as well as their sensitivity to socioeconomic disparities.
What this study does not show
This study does not provide evidence for the clinical utility of epigenetic clocks in predicting health outcomes based on the test results.
Evidence scorecard
- Analytic validity: Established
- Clinical validity: Partial
- Clinical utility: Not established
The data for this study were derived from the UK Household Longitudinal Study, which included DNAm profiles and socioeconomic measures. Delta age, defined as the difference between DNAm age and chronological age, was calculated using linear mixed-effects models. These models assessed delta age based on clock type, age group, sex, and interactions with socioeconomic status, including education, occupation, and income.
The findings revealed substantial variation in delta age across the different clocks and age groups. The first-generation Horvath clock was found to overestimate age in younger individuals while underestimating it in older individuals. In contrast, the second-generation PhenoAge clock consistently showed a negative delta age, indicating a slower rate of biological aging. The third-generation DunedinPoAm clock exhibited minimal deviation and stable calibration across the population.
Furthermore, the study highlighted that while the Horvath clocks exhibited weak or inconsistent associations with socioeconomic factors, the PhenoAge and DunedinPoAm clocks captured clearer socioeconomic gradients. Specifically, higher levels of education and income were associated with lower delta age, suggesting that individuals with more resources may experience slower epigenetic aging.
These results underscore the importance of selecting the appropriate epigenetic clock for research, particularly in studies examining health inequalities and their biological embodiment. The authors advocate for longitudinal validation of these clocks across diverse populations and life stages to enhance their applicability in aging research.